Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 2014

View Archived Issues

Eisai begins phase III trial of eribulin mesilate in metastatic breast cancer

Epizyme achieves lead candidate selection milestone in GSK collaboration

Phase III femoral nerve block study of Exparel meets primary endpoint

Teva presents phase II results for laquinimod in Crohn's disease

Human recombinant peptide sponge developed as ischemic stroke cell therapy scaffold

Alnylam Pharmaceuticals closes alliance with Genzyme

Aires Pharmaceuticals is now a subsidiary of Mast Therapeutics

Protective mechanisms for cancer brain metastases identified

Cadazolid receives FDA QIDP designation for Clostridium difficile-associated diarrhea

Galapagos provides update on GSK-2586184 in psoriasis, lupus and ulcerative colitis

Merck & Co. patents novel ROR-gamma inhibitors

Biotie decides to develop SYN-120 internally, gives update on Neurelis acquisition

Celsion reports interim data from phase II DIGNITY trial in breast cancer

Pernix Therapeutics signs agreement with Osmotica Pharmaceutical to promote Khedezla

Canadian researchers prepare new vaccines for chlamydial infection

Intraparenchymal transplantation of SB-623 leads to neurological improvements in phase I/II trials

Scientists at Merck KGaA disclose novel PARP-1/TANK inhibitors

New fusion proteins designed for cancer and autoimmune diseases

European CHMP recommends approval of tablet formulation of Noxafil

Roche patents new immunocytokines for inflammatory diseases

Roche and Discuva collaborate on antibiotics against multidrug-resistant bacteria

Promacta submitted to FDA for severe aplastic anemia

Bayer Yakuhin seeks Japanese approval of Eylea for diabetic macular edema

Cell Therapeutics initiates PERSIST-2 trial of pacritinib in myelofibrosis

Endo and Paladin Labs combine to form Endo International

Data monitoring committee recommends termination of METLung study of onartuzumab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...